Targeted Metallo-Drugs: Design, Development, and Modes of Action (Metal Ions in Li...

[0dayddl]

pdf | 21.29 MB | English | Isbn:‎ B0C3WNPRZD | Author: Etelka Farkas, Celine J. Marmion, Astrid Sigel, Helmut Sigel; Eva Freisinger, Roland K. O. Sigel | Year: 2023

Description:

Volume 24, entitled Targeted Metallo-Drugs: Design, Development, and Modes of Action, of the series Metal Ions in Life Sciences (MILS), fosters inter-disciplinary research in the vibrant field of Biological Inorganic Chemistry . Inspired by the clinical success of cisplatin as a leading anticancer drug but mindful of the shortcomings associated with its use including dose-limiting toxic side effects and acquired or intrinsic drug resistance, scientists across the globe have been endeavoring to identify new metallo-drugs for therapeutic exploitation. This has led to innovative metallo-drug candidates that (i) enhance cancer cell selectivity, thus reducing toxic side effects, and/or (ii) possess new modes of action to improve efficacy and also target resistance pathways. This and more are captured in MILS- 24 which consists of 12 comprehensive, well-illustrated, and up to date chapters with over 1600 citations, 100 figures, and 10 tables with key contributions from 32 international experts from Europe, Asia, and North and South America. MILS- 24 not only keeps the scientific community abreast of latest developments, it also serves as an invaluable resource to stimulate further research on targeted metallo-drug design and development.

• It covers anticancer, antimicrobial, antiviral, and other agents, such as those targeting tropical diseases and cyanide poisoning and radiometals in molecular imaging and therapy.

• It highlights recent metallo-drug developments targeting COVID-19.

• It features advanced spectroscopic methods and metallomics as important tools to elucidate the modes of actions of metallo-drugs.

A kódrészlet megtekintéséhez be kell jelentkezned, vagy nincs jogosultságod a tartalom megtekintéséhez.

A kódrészlet megtekintéséhez be kell jelentkezned, vagy nincs jogosultságod a tartalom megtekintéséhez.